iShares US Pharmaceuticals ETF
130 hedge funds and large institutions have $140M invested in iShares US Pharmaceuticals ETF in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 33 increasing their positions, 32 reducing their positions, and 3 closing their positions.
600% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 3
169% more call options, than puts
Call options by funds: $651K | Put options by funds: $242K
19% more capital invested
Capital invested by funds: $118M → $140M (+$22.1M)
15% more funds holding
Funds holding: 113 → 130 (+17)
7.34% more ownership
Funds ownership: 92.89% → 100.23% (+7.3%)
3% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.95M |
| 2 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
+$3.59M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$3.05M |
| 4 |
Goldman Sachs
New York
|
+$2.42M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$4.04M |
| 2 |
CCT
Chemung Canal Trust
Elmira,
New York
|
-$2.76M |
| 3 |
FMP
Financial Management Professionals
Austin,
Texas
|
-$2.72M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$645K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$459K |
IHE Hedge Fund Activity: Q4 2022 in Review
130 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2022, worth a combined $140M — up 19% from $118M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IHE positions and 3 closed out — a net gain of 18 holders — while 33 added to existing stakes and 32 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.95M. The largest seller was Bank of America, cutting an estimated $4.04M.
- 130 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2022, up from 113 in Q3 2022.
- Funds reported $140M of iShares US Pharmaceuticals ETF stock for Q4 2022, up 19% quarter-over-quarter.
- 21 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2022 and 3 closed out, a net change of +18 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2022 was Morgan Stanley, an estimated $3.95M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2022 was Bank of America, an estimated $4.04M sold.
Based on aggregated 13F filings for Q4 2022.